Hosted on MSN15d
Viking Therapeutics targets Phase 3 trials for VK2735 in Q2 2025 amid strong clinical progressCEO Brian Lian highlighted 2024 as an exceptionally ... as higher doses are explored in oral VK2735 trials. Viking Therapeutics showcased significant clinical progress across its pipeline in ...
Hello and thank you all for participating in today's call. Joining me today is Brian Lian, Viking's President and CEO; and Greg Zante, Viking's CFO. Before we begin, I'd like to caution that ...
2024 was an exciting and extremely productive year for Viking,” stated Brian Lian, Ph.D., chief executive ... TipRanks >> Read More on VKTX: Viking Therapeutics NewsMORE Related Stocks Indices ...
The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA. Read More on VKTX: Viking Therapeutics NewsMORE Related Stocks Indices ...
Welcome to the Viking Therapeutics Fourth Quarter and Full ... Joining me today is Brian Lian, Viking's President and CEO; and Greg Zante, Viking's CFO. Before we begin, I'd like to caution ...
I would now like to turn the conference over to Viking's Manager of Investor Relations, Stephanie Diaz. Please go ahead, Stephanie. Hello and thank you all for participating in today's call. Joining ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results